Tigermed (Stock code: 300347.SZ/3347.HK) is a leading provider of innovative clinical research solutions across the full life cycle of biopharmaceutical and medical device products globally. With a broad portfolio of services and a promise of quality, from clinical development to commercialization, we are committed to moving our customers and patients through their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 80 subsidiaries and 170 offices and sites, with over 8,600 employees across 51 countries in Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables boundless possibility for healthcare industry, embracing challenges to fulfill our commitment to serve unmet patients' needs, and eventually saving lives.
Unlock the market timeline & signal feed
7 signals in the last 90 days.
The order this company entered each market — oldest to newest
Clinical Project Manager
Clinical Research Associate
Sign up to see the full signal feed
How Tigermed's international expansion compares to its competitors
TigermedYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 TigermedYou | 6 | 1 | +33% | 7 | 33 |
Clinical Project Manager_Taiwan Base_Support Australia
View postingTaiwan · yesterday
Contractor Project Manager
View postingAustralia · yesterday
RA Specialist_Turkey
View postingTürkiye · 2d ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Insilico Medicine, backed by Qiming Venture Partners, listed on HKEX as 2025's largest biotech IPO, valued at HK$19.51 billion. The AI-driven drug discovery company aims to extend human healthspan.
Zhou Zhifeng of Qiming Ventures ranked 80th on Forbes 2026 Midas List, first Chinese tech/AI investor on list. His portfolio includes Biren, Zhipu, and other AI companies.
Alex Zhou, Managing Partner at Qiming Venture Partners, debuts at No. 80 on Forbes 2026 Midas List, recognized for his AI and technology investments with four portfolio IPOs in 2026.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Tigermed's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
